ITB vs XBI
iShares US Home Construction ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for ITB.
- • ITB pays a higher dividend yield (1.18%).
Side-by-side metrics
| Metric | ITB | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.18% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $2.54B | $8.30B |
YTD return | -0.83% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.72 | 1.09 |
P/E ratio | 15.14 | — |
Last price | $92.93 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
ITB top holdings
| DHI | D.R. Horton Inc | 15.83% |
| PHM | PulteGroup Inc | 8.98% |
| LEN | Lennar Corp Class A | 7.44% |
| NVR | NVR Inc | 6.74% |
| TOL | Toll Brothers Inc | 5.14% |
| BLD | TopBuild Corp | 4.72% |
| SHW | Sherwin-Williams Co | 4.42% |
| LOW | Lowe's Companies Inc | 4.29% |
| HD | The Home Depot Inc | 4.16% |
| LII | Lennox International Inc | 3.58% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About ITB
ITB (iShares US Home Construction ETF) is US homebuilding and construction companies. Managed by iShares, the fund carries $2.5B in assets under management, an expense ratio of 0.38%, a dividend yield of 1.18%. Its largest holding is D.R. Horton Inc (DHI), which represents 15.8% of the portfolio. Real Estate is the fund's largest sector exposure at 0.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.